Zobrazeno 1 - 10
of 631
pro vyhledávání: '"Dhadda, A."'
Autor:
Lawrence S. Honig, Marwan N. Sabbagh, Christopher H. van Dyck, Reisa A. Sperling, Steven Hersch, Andre Matta, Luigi Giorgi, Michelle Gee, Michio Kanekiyo, David Li, Derk Purcell, Shobha Dhadda, Michael Irizarry, Lynn Kramer
Publikováno v:
Alzheimer’s Research & Therapy, Vol 16, Iss 1, Pp 1-4 (2024)
Externí odkaz:
https://doaj.org/article/235d44fcb4a64fba89f8c186629bc9ac
Autor:
Ngu Wah Than, D. Mark Pritchard, David M. Hughes, Kai Shing Yu, Helen S. Minnaar, Amandeep Dhadda, Jamie Mills, Joakim Folkesson, Calin Radu, C.A. Duckworth, Helen Wong, Muneeb Ul Haq, Rajaram Sripadam, Mark D. Halling-Brown, Alexandra J. Stewart, Arthur Sun Myint
Publikováno v:
Clinical and Translational Radiation Oncology, Vol 49, Iss , Pp 100851- (2024)
Background and purpose: Radical surgery is the standard of care for early rectal cancer. However, alternative organ-preserving approaches are attractive, especially in frail or elderly patients as these avoid surgical complications. We have assessed
Externí odkaz:
https://doaj.org/article/e94040b3366b45e39646e1e4bbf99ec1
Autor:
Lawrence S. Honig, Marwan N. Sabbagh, Christopher H. van Dyck, Reisa A. Sperling, Steven Hersch, Andre Matta, Luigi Giorgi, Michelle Gee, Michio Kanekiyo, David Li, Derk Purcell, Shobha Dhadda, Michael Irizarry, Lynn Kramer
Publikováno v:
Alzheimer’s Research & Therapy, Vol 16, Iss 1, Pp 1-12 (2024)
Abstract Background Alzheimer disease (AD) is a major health problem of aging, with tremendous burden on healthcare systems, patients, and families globally. Lecanemab, an FDA-approved amyloid beta (Aβ)-directed antibody indicated for the treatment
Externí odkaz:
https://doaj.org/article/37323811cfca4e539a625fdbaee2b067
Autor:
Viswanath Devanarayan, Daniel A. Llano, Yan Helen Hu, Harald Hampel, Lynn Kramer, Shobha Dhadda, Michael Irizarry
Publikováno v:
Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring, Vol 16, Iss 3, Pp n/a-n/a (2024)
Abstract Plasma pTau181, a marker of amyloid and tau burden, was evaluated as a prognostic predictor of clinical decline and Alzheimer's disease (AD) progression of amyloid‐positive (Aβ+) patients with mild cognitive impairment (MCI). The training
Externí odkaz:
https://doaj.org/article/213befed8ac54b48976227fe3b8e2375
Autor:
Wah Than, Ngu, Mark Pritchard, D., Hughes, David M., Shing Yu, Kai, Minnaar, Helen S., Dhadda, Amandeep, Mills, Jamie, Folkesson, Joakim, Radu, Calin, Duckworth, C.A., Wong, Helen, Ul Haq, Muneeb, Sripadam, Rajaram, Halling-Brown, Mark D., Stewart, Alexandra J., Sun Myint, Arthur
Publikováno v:
In Clinical and Translational Radiation Oncology November 2024 49
Autor:
Clayon Hamilton, Annette Berndt, Lucy Kervin, Laura Kadowaki, Janice Sorensen, Akber Mithani, Simran Dhadda, Abeera Irfan, Emma Leong
Publikováno v:
BMJ Open Quality, Vol 13, Iss 2 (2024)
Background The devastating impact of the COVID-19 pandemic on long-term care (LTC) homes underscores the importance of effective pandemic preparedness and response. This mixed-methods, implementation science study investigated how a virtual-based qua
Externí odkaz:
https://doaj.org/article/d8b37d9131d04f60a037a997de64884f
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Kathleen A. Welsh‐Bohmer, Geoffrey A. Kerchner, Shobha Dhadda, Miguel Garcia, David S. Miller, Fanni Natanegara, Lars Lau Raket, Weining Robieson, Eric R. Siemers, Maria C. Carrillo, Christopher J. Weber
Publikováno v:
Alzheimer’s & Dementia: Translational Research & Clinical Interventions, Vol 9, Iss 4, Pp n/a-n/a (2023)
Abstract The efficient and accurate execution of clinical trials testing novel treatments for Alzheimer's disease (AD) is a critical component of the field's collective efforts to develop effective disease‐modifying treatments for AD. The lengthy a
Externí odkaz:
https://doaj.org/article/b8fe5eb288c64421be7d95e7fa3df0d5
Autor:
Eric McDade, Jeffrey L. Cummings, Shobha Dhadda, Chad J. Swanson, Larisa Reyderman, Michio Kanekiyo, Akihiko Koyama, Michael Irizarry, Lynn D. Kramer, Randall J. Bateman
Publikováno v:
Alzheimer’s Research & Therapy, Vol 14, Iss 1, Pp 1-17 (2022)
Abstract Background Lecanemab, a humanized IgG1 monoclonal antibody that targets soluble aggregated Aβ species (protofibrils), has demonstrated robust brain fibrillar amyloid reduction and slowing of clinical decline in early AD. The objective of th
Externí odkaz:
https://doaj.org/article/a6d9281674a5413f8b67e7a74816d854